Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Omega Therapeutics, Inc. (OMGA : NSDQ)

• Company Description    Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass. Number of Employees: 80

• Price / Volume Information    Yesterday's Closing Price: $2.71 Daily Weekly Monthly 20 Day Moving Average: 171,194 shares Shares Outstanding: 47.85 (millions) Market Capitalization: $129.67 (millions) Beta: 52 Week High: $31.41 52 Week Low: $2.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -40.31% -32.78% 12 Week -75.74% -73.33% Year To Date -76.08% -70.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 ACORN PARK DRIVE - CAMBRIDGE,MA 02140 USA ph: 617-949-4360 fax: - argotomega@argotpartners.com http://www.omegatherapeutics.com

• General Corporate Information    Officers Mahesh Karande - President; Chief Executive Officer and Director Noubar B. Afeyan - Chairman of the Board of Directors Roger Sawhney - Chief Financial Officer Thomas McCauley - Chief Scientific Officer Yan Moore - Chief Medical Officer Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68217N105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/09/22 Share - Related Items Shares Outstanding: 47.85 Most Recent Split Date: (:1) Beta: Market Capitalization: $129.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 4.55% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 86.11% ROE 03/31/22 - -58.81 12/31/21 - -83.15 09/30/21 - - ROA 03/31/22 - -36.39 12/31/21 - -45.02 09/30/21 - - Current Ratio 03/31/22 - 15.23 12/31/21 - 19.13 09/30/21 - 16.69 Quick Ratio 03/31/22 - 15.23 12/31/21 - 19.13 09/30/21 - 16.69 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -18,193.20 12/31/21 - -47,416.67 09/30/21 - - Book Value 03/31/22 - 3.79 12/31/21 - 4.20 09/30/21 - 4.61 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.11 12/31/21 - 0.10 09/30/21 - 0.03 Debt-to-Capital 03/31/22 - 9.88 12/31/21 - 9.01 09/30/21 - 3.29

Powered by Zacks Investment Research ©